Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

May 6, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

September 30, 2027

Conditions
B-cell MalignancyNon-Hodgkin LymphomaMantle Cell LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWaldenström MacroglobulinemiaMarginal Zone LymphomaFollicular LymphomaDLBCL UnclassifiableRichter's Transformation
Interventions
DRUG

BGB-16673

Orally administered

Trial Locations (29)

100000

RECRUITING

Peking University Third Hospital, Beijing

100020

RECRUITING

Beijing Chao Yang Hospital,Capital Medical University, Beijing

116001

RECRUITING

Affiliated Zhongshan Hospital of Dalian University, Dalian

130021

RECRUITING

The First Hospital of Jilin University, Changchun

200025

RECRUITING

Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai

210029

RECRUITING

Jiangsu Province Hospital, Nanjing

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

230000

RECRUITING

Anhui Provincial Hospital, Hefei

233004

RECRUITING

The First Affiliated Hospital of Bengbu Medical University, Bengbu

250117

RECRUITING

Shandong Cancer Hospital, Jinan

266031

RECRUITING

Qingdao Central Hospital, Qingdao

300020

RECRUITING

Institute of Hematology and Hospital of Blood Disease, Tianjin

311121

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine Branch Yuhang, Hangzhou

325000

RECRUITING

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

330006

RECRUITING

The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang

330029

RECRUITING

Jiangxi Province Cancer Hospital, Nanchang

350001

RECRUITING

Fujian Medical University Union Hospital, Fuzhou

400037

RECRUITING

Second Affiliated Hospital of Army Medical University (Xinqiao Hospital), Chongqing

410011

RECRUITING

The Second Xiangya Hospital of Central South University, Changsha

430022

RECRUITING

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

441021

RECRUITING

Xiangyang Central Hospital, Xiangyang

450000

RECRUITING

Henan Cancer Hospital, Zhengzhou

473000

RECRUITING

Nanyang Central Hospital, Nanyang

510060

RECRUITING

Sun Yat Sen University Cancer Center, Guangzhou

510120

RECRUITING

Guangdong Provincial Peoples Hospital Huifu Branch, Guangzhou

530021

RECRUITING

The Peoples Hospital of Guangxi Zhuang Autonomous Region, Nanning

610041

RECRUITING

West China Hospital, Sichuan University, Chengdu

650032

RECRUITING

First Affiliated Hospital of Kunming Medical University, Kunming

030013

RECRUITING

Shanxi Provincial Cancer Hospital, Taiyuan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT05294731 - Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | Biotech Hunter | Biotech Hunter